Scott Joseph Antonia

Journal article iScience · August 21, 2026 Many epithelial cancers orchestrate prognostically significant intratumoral tertiary lymphoid structures (TLSs), yet the mechanisms behind their antitumor activity remain unclear. Here we show that intratumoral TLS in ∼14% of human high-grade serous ovaria ... Full text Link to item Cite

Tumor-infiltrating plasma cell profiling after PD-1 blockade reveals tumor-specific antibodies.

Journal article Cancer Cell · July 27, 2026 The role of tumor-infiltrating B cells (TIL-Bs) in shaping anti-tumor responses in the context of immune checkpoint blockade remains incompletely understood. Here, we interrogate the humoral response in resected lung tumors from patients with non-small cel ... Full text Link to item Cite

Alirocumab plus cemiplimab in advanced immuno-refractory metastatic non-small cell lung cancer: an ongoing multi-center phase II study.

Journal article Future Oncol · April 2026 Immunotherapy resistance represents a major unmet clinical need for patients with metastatic non-small cell lung cancer (NSCLC). Preclinical studies have identified PCSK9 as an immunosuppressive regulator of antigen presentation, providing a compelling rat ... Full text Link to item Cite

Distinct Tumor-Immune Ecologies in Patients with Lung Cancer Predict Progression and Define a Clinical Biomarker of Therapy Response.

Journal article Cancer Res · March 2, 2026 UNLABELLED: Multiplexed imaging of tissues is an approach that holds promise for improving early detection, diagnosis, and treatment of cancer. In this study, we investigated multiplexed histologic images of paired pretreatment and on-treatment samples fro ... Full text Link to item Cite

Addressing Common Medications That Influence Immunotherapy Response in Solid Tumors.

Journal article J Clin Oncol · March 2026 Full text Link to item Cite

Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): conventional and distribution-based immune profiling of the tumor microenvironment and peripheral circulation.

Journal article J Immunother Cancer · October 31, 2025 PURPOSE: A recently published phase 2 neoadjuvant trial in patients with early-stage non-small cell lung cancer (NSCLC) (NCT02818920) evaluated the potential efficacy of pembrolizumab administration in the absence of chemotherapy. This communication report ... Full text Link to item Cite

Improving lung cancer tumor-infiltrating lymphocyte (TIL) manufacturing.

Journal article Cytotherapy · October 2025 BACKGROUND: The successful treatment of melanoma using autologous in vitro expanded tumor infiltrating lymphocytes (TILs) has sparked clinical trials for the assessment of TIL efficacy against other cancers, including non-small cell lung cancer (NSCLC). Th ... Full text Link to item Cite

A Critical Review of Immunomodulation in the Management of Inoperable Stage III NSCLC.

Journal article Cancers (Basel) · May 30, 2025 The current standard of care for inoperable stage III non-small cell lung cancer (NSCLC) is concurrent chemotherapy and radiation therapy with consolidation durvalumab. Despite this approach, about 50% of patients will experience disease recurrence, with a ... Full text Link to item Cite

Impaired T cell and neoantigen retention in time-serial analysis of metastatic non-small cell lung cancer in patients unresponsive to TIL cell therapy.

Journal article Nat Cancer · May 2025 Cell therapy with tumor-infiltrating lymphocytes (TILs) has yielded durable responses for multiple cancer types, but the causes of therapeutic resistance remain largely unknown. Here multidimensional analysis was performed on time-serial tumor and blood in ... Full text Link to item Cite

Perioperative pembrolizumab in early-stage non-small cell lung cancer (NSCLC): safety, efficacy, and exploratory biomarker analysis.

Journal article J Immunother Cancer · February 4, 2025 BACKGROUND: Our study was designed to determine the safety, efficacy, and immunological effects of perioperative pembrolizumab in early-stage NSCLC. METHODS: This is a single-arm phase II study of perioperative pembrolizumab in patients with untreated, cli ... Full text Link to item Cite

Complement factor H targeting antibody GT103 in refractory non-small cell lung cancer: a phase 1b dose escalation trial.

Journal article Nat Commun · January 2, 2025 GT103 is a first-in-class, fully human, IgG3 monoclonal antibody targeting complement factor H that kills tumor cells and promotes anti-cancer immunity in preclinical models. We conducted a first-in-human phase 1b study dose escalation trial of GT103 in re ... Full text Open Access Link to item Cite

Oncolytic adenovirus MEM-288 encoding membrane-stable CD40L and IFNβ induces an anti-tumor immune response in high grade serous ovarian cancer.

Journal article Neoplasia · November 2024 Single agent immune checkpoint inhibitors have been ineffective for patients with advanced stage and recurrent high grade serous ovarian cancer (HGSOC). Using pre-clinical models of HGSOC, we evaluated the anti-tumor and immune stimulatory effects of an on ... Full text Link to item Cite

Differences in microenvironment of lung cancer and pleural effusions by single-cell RNA sequencing.

Journal article Lung Cancer · July 2024 BACKGROUND: Direct comparison of tumor microenvironment of matched lung cancer biopsies and pleural effusions (PE) from the same patients is critical in understanding tumor biology but has not been performed. This is the first study to compare the lung can ... Full text Link to item Cite

Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC.

Journal article JTO Clin Res Rep · March 2024 INTRODUCTION: In the placebo-controlled, phase 3 PACIFIC trial, durvalumab significantly prolonged progression-free survival (PFS) (p < 0.0001) and overall survival (OS) (p = 0.00251) in patients with unresectable stage III NSCLC and no progression after p ... Full text Link to item Cite

Differential roles of normal and lung cancer-associated fibroblasts in microvascular network formation.

Journal article APL Bioeng · March 2024 Perfusable microvascular networks offer promising three-dimensional in vitro models to study normal and compromised vascular tissues as well as phenomena such as cancer cell metastasis. Engineering of these microvascular networks generally involves the use ... Full text Link to item Cite

Phase I study of peposertib and avelumab with or without palliative radiotherapy in patients with advanced solid tumors.

Journal article ESMO Open · February 2024 INTRODUCTION: We report results from a phase I, three-part, dose-escalation study of peposertib, a DNA-dependent protein kinase inhibitor, in combination with avelumab, an immune checkpoint inhibitor, with or without radiotherapy in patients with advanced ... Full text Link to item Cite

Transcriptional and epigenetic regulators of human CD8+ T cell function identified through orthogonal CRISPR screens.

Journal article Nat Genet · December 2023 Clinical response to adoptive T cell therapies is associated with the transcriptional and epigenetic state of the cell product. Thus, discovery of regulators of T cell gene networks and their corresponding phenotypes has potential to improve T cell therapi ... Full text Link to item Cite

Survivin Dendritic Cell Vaccine Safely Induces Immune Responses and Is Associated with Durable Disease Control after Autologous Transplant in Patients with Myeloma.

Journal article Clin Cancer Res · November 14, 2023 PURPOSE: We investigated whether a dendritic cell (DC) vaccine transduced with an adenoviral vector encoded with full-length survivin (Ad-S), with mutations neutralizing its antiapoptotic function, could safely generate an immune response and deepen clinic ... Full text Link to item Cite

Brief Report: Safety and Antitumor Activity of Durvalumab Plus Tremelimumab in Programmed Cell Death-(Ligand)1-Monotherapy Pretreated, Advanced NSCLC: Results From a Phase 1b Clinical Trial.

Journal article J Thorac Oncol · August 2023 INTRODUCTION: Although first-line immunotherapy approaches are standard, in patients with non-small cell lung cancer (NSCLC) previously treated with programmed cell death protein-1 or programmed death-(ligand)1 (PD-[L]1) inhibitors, the activity of combine ... Full text Link to item Cite

A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.

Journal article BMC Cancer · July 28, 2023 BACKGROUND: In this phase Ib/II open-label study, tumor immune suppression was targeted in patients with advanced refractory solid tumors and patients with recurrent/refractory non-small cell lung cancer (NSCLC) using galunisertib with nivolumab. METHODS: ... Full text Link to item Cite

Dose-Limiting Pulmonary Toxicity in a Phase 1/2 Study of Radiation and Chemotherapy with Ipilimumab Followed by Nivolumab for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer.

Journal article Int J Radiat Oncol Biol Phys · July 15, 2023 PURPOSE: We hypothesized that concurrent ipilimumab with chemoradiationtherapy (chemoRT) followed by maintenance nivolumab would be safe for patients with unresectable stage III non-small cell lung cancer (NSCLC). We aimed to assess the safety (phase 1) an ... Full text Link to item Cite

High Yield of Pleural Cell-Free DNA for Diagnosis of Oncogenic Mutations in Lung Adenocarcinoma.

Journal article Chest · July 2023 BACKGROUND: Pleural cytology is currently used to assess targetable mutations in patients with advanced lung adenocarcinoma. However, it is fraught with low diagnostic yield. RESEARCH QUESTION: Can pleural cell-free DNA (cfDNA) be used to assess targetable ... Full text Link to item Cite

Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites.

Journal article Cancer Immunol Immunother · June 2023 Radiation therapy (RT) can prime and boost systemic anti-tumor effects via STING activation, resulting in enhanced tumor antigen presentation and antigen recognition by T cells. It is increasingly recognized that optimal anti-tumor immune responses benefit ... Full text Link to item Cite

Brief Report: Durvalumab After Chemoradiotherapy in Unresectable Stage III EGFR-Mutant NSCLC: A Post Hoc Subgroup Analysis From PACIFIC.

Journal article J Thorac Oncol · May 2023 INTRODUCTION: Consolidation durvalumab (the "PACIFIC regimen") is standard of care for patients with unresectable stage III NSCLC who have not progressed after chemoradiotherapy, on the basis of data from the phase 3 placebo-controlled PACIFIC study (NCT02 ... Full text Link to item Cite

Combination IFNβ and Membrane-Stable CD40L Maximize Tumor Dendritic Cell Activation and Lymph Node Trafficking to Elicit Systemic T-cell Immunity.

Journal article Cancer Immunol Res · April 3, 2023 Oncolytic virus therapies induce the direct killing of tumor cells and activation of conventional dendritic cells (cDC); however, cDC activation has not been optimized with current therapies. We evaluated the adenoviral delivery of engineered membrane-stab ... Full text Link to item Cite

A single-arm, multicenter, phase II trial of osimertinib in patients with epidermal growth factor receptor exon 18 G719X, exon 20 S768I, or exon 21 L861Q mutations.

Journal article ESMO Open · April 2023 BACKGROUND: For patients with stage IV non-small-cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions and exon 21 L858R mutations, osimertinib is the standard of care. Investigating the activity and safety of osimertinib in patie ... Full text Link to item Cite

Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study.

Journal article Lung Cancer · January 2023 OBJECTIVES: There are limited real-world data about patient-reported outcomes with immunotherapies (IO) in metastatic non-small cell lung cancer (mNSCLC). We describe patient-reported distress and clinical outcomes with IO-based treatments or cytotoxic che ... Full text Link to item Cite

Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer.

Journal article Future Oncol · December 2022 Background: Trends/outcomes associated with National Comprehensive Cancer Network (NCCN)-recommended biomarker testing to guide advanced non-small-cell lung cancer (aNSCLC) treatment were assessed. Methods: Patients initiating first-line aNSCLC treatment w ... Full text Link to item Cite

Peroxynitrite in the tumor microenvironment changes the profile of antigens allowing escape from cancer immunotherapy.

Journal article Cancer Cell · October 10, 2022 Cancer immunotherapy often depends on recognition of peptide epitopes by cytotoxic T lymphocytes (CTLs). The tumor microenvironment (TME) is enriched for peroxynitrite (PNT), a potent oxidant produced by infiltrating myeloid cells and some tumor cells. We ... Full text Link to item Cite

Characterizing the Shifting Real-World Treatment Landscape by PD-L1 Testing Status and Expression Level in Advanced Non-Small Cell Lung Cancer.

Journal article Adv Ther · October 2022 INTRODUCTION: Contemporary real-world data on advanced non-small cell lung cancer (aNSCLC) treatment patterns across programmed cell death-ligand 1 (PD-L1) expression levels and testing status are limited. METHODS: A retrospective cohort was selected of ad ... Full text Link to item Cite

IGF-binding proteins secreted by cancer-associated fibroblasts induce context-dependent drug sensitization of lung cancer cells.

Journal article Sci Signal · August 16, 2022 Cancer-associated fibroblasts (CAFs) in the tumor microenvironment are often linked to drug resistance. Here, we found that coculture with CAFs or culture in CAF-conditioned medium unexpectedly induced drug sensitivity in certain lung cancer cell lines. Ge ... Full text Link to item Cite

Mistic: An open-source multiplexed image t-SNE viewer.

Journal article Patterns (N Y) · July 8, 2022 Understanding the complex ecology of a tumor tissue and the spatiotemporal relationships between its cellular and microenvironment components is becoming a key component of translational research, especially in immuno-oncology. The generation and analysis ... Full text Link to item Cite

Patient-derived micro-organospheres enable clinical precision oncology.

Journal article Cell Stem Cell · June 2, 2022 Patient-derived xenografts (PDXs) and patient-derived organoids (PDOs) have been shown to model clinical response to cancer therapy. However, it remains challenging to use these models to guide timely clinical decisions for cancer patients. Here, we used d ... Full text Open Access Link to item Cite

Phase I Study of Taminadenant (PBF509/NIR178), an Adenosine 2A Receptor Antagonist, with or without Spartalizumab (PDR001), in Patients with Advanced Non-Small Cell Lung Cancer.

Journal article Clin Cancer Res · June 1, 2022 PURPOSE: The adenosine 2A receptor (A2AR) mediates the immunosuppressive effects of adenosine in the tumor microenvironment and is highly expressed in non-small cell lung cancer (NSCLC). Taminadenant (PBF509/NIR178) is an A2AR antagonist able to reactivate ... Full text Link to item Cite

A Phase 2 Clinical Trial of Combination Nivolumab, Ipilimumab, and Paclitaxel in Patients With Untreated Metastatic NSCLC: The OPTIMAL Trial.

Journal article JTO Clin Res Rep · June 2022 INTRODUCTION: Most patients with advanced NSCLC will experience disease progression and death within 2 years. Novel approaches are needed to improve outcomes. METHODS: We conducted an open-label, nonrandomized, phase 2 trial in patients with treatment-naiv ... Full text Link to item Cite

First-line nivolumab plus ipilimumab versus chemotherapy for the treatment of unresectable malignant pleural mesothelioma: patient-reported outcomes in CheckMate 743.

Journal article Lung Cancer · May 2022 OBJECTIVE: In CheckMate 743 (NCT02899299), nivolumab + ipilimumab significantly prolonged overall survival in patients with unresectable malignant pleural mesothelioma (MPM). We present patient-reported outcomes (PROs). MATERIALS AND METHODS: Patients (N = ... Full text Link to item Cite

Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of lung cancer and mesothelioma.

Journal article J Immunother Cancer · May 2022 Immunotherapy has transformed lung cancer care in recent years. In addition to providing durable responses and prolonged survival outcomes for a subset of patients with heavily pretreated non-small cell lung cancer (NSCLC), immune checkpoint inhibitors (IC ... Full text Link to item Cite

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Journal article J Clin Oncol · April 20, 2022 PURPOSE: The phase III PACIFIC trial compared durvalumab with placebo in patients with unresectable, stage III non-small-cell lung cancer and no disease progression after concurrent chemoradiotherapy. Consolidation durvalumab was associated with significan ... Full text Link to item Cite

Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial.

Journal article ESMO Open · April 2022 BACKGROUND: The phase III PACIFIC trial (NCT02125461) established consolidation durvalumab as standard of care for patients with unresectable, stage III non-small-cell lung cancer (NSCLC) and no disease progression following chemoradiotherapy (CRT). In som ... Full text Link to item Cite

Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.

Journal article Lung Cancer · April 2022 INTRODUCTION: Immune-mediated adverse events (imAEs), including all-cause immune-mediated pneumonitis, were reported in approximately 25% of patients in the placebo-controlled, phase III PACIFIC trial of durvalumab monotherapy (for up to 12 months) in pati ... Full text Link to item Cite

Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial.

Journal article J Immunother Cancer · April 2022 BACKGROUND: Availability of checkpoint inhibitors has created a paradigm shift in the management of patients with solid tumors. Despite this, most patients do not respond to immunotherapy, and there is considerable interest in developing combination therap ... Full text Link to item Cite

Interaction of bacterial genera associated with therapeutic response to immune checkpoint PD-1 blockade in a United States cohort.

Journal article Genome Med · March 29, 2022 BACKGROUND: Recent studies show that human gut microbial composition can determine whether a patient is a responder or non-responder to immunotherapy but have not identified a common microbial signal shared by responding patients. The functional relationsh ... Full text Link to item Cite

Managing Resistance to Immune Checkpoint Inhibitors in Lung Cancer: Treatment and Novel Strategies.

Journal article J Clin Oncol · February 20, 2022 A proportion of patients with lung cancer experience long-term clinical benefit with immune checkpoint inhibitors (ICIs). However, most patients develop disease progression during treatment or after treatment discontinuation. Definitions of immune resistan ... Full text Link to item Cite

Clinical Trials with Biologic Primary Endpoints in Immuno-oncology: Concepts and Usage.

Journal article Clin Cancer Res · January 1, 2022 Clinical trials that have a pharmacokinetic or a pharmacodynamic immunologic mechanism of action-based primary outcome could substantially improve the validity and efficiency of early development of immuno-oncology agents. Here, we outline different trial ... Full text Link to item Cite

Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small-cell lung cancer.

Journal article Ann Oncol · December 2021 Acquired resistance (AR) to programmed cell death protein 1/programmed death-ligand 1 [PD-(L)1] blockade is frequent in non-small-cell lung cancer (NSCLC), occurring in a majority of initial responders. Patients with AR may have unique properties of persis ... Full text Link to item Cite

Durvalumab After Concurrent Chemoradiotherapy in Elderly Patients With Unresectable Stage III Non-Small-Cell Lung Cancer (PACIFIC).

Journal article Clin Lung Cancer · November 2021 BACKGROUND: The PACIFIC trial demonstrated that consolidation durvalumab significantly improved PFS and OS (the primary endpoints) vs. placebo in patients with unresectable, stage III NSCLC whose disease had not progressed after platinum-based, concurrent ... Full text Link to item Cite

Immune Checkpoint Inhibitors in the Aged.

Journal article Curr Oncol Rep · August 3, 2021 PURPOSE OF REVIEW: Large phase III trials have established the benefit of checkpoint blockade across multiple tumor types, but patient representation is limited in some subgroups including the aged population. There are several changes in the immune system ... Full text Link to item Cite

Tumor-infiltrating lymphocyte treatment for anti-PD-1-resistant metastatic lung cancer: a phase 1 trial.

Journal article Nat Med · August 2021 Adoptive cell therapy using tumor-infiltrating lymphocytes (TILs) has shown activity in melanoma, but has not been previously evaluated in metastatic non-small cell lung cancer. We conducted a single-arm open-label phase 1 trial ( NCT03215810 ) of TILs adm ... Full text Link to item Cite

Characterization of Sentinel Lymph Node Immune Signatures and Implications for Risk Stratification for Adjuvant Therapy in Melanoma.

Journal article Ann Surg Oncol · July 2021 BACKGROUND: Although sentinel lymph node (SLN) biopsy is a standard procedure used to identify patients at risk for melanoma recurrence, it fails to risk-stratify certain patients accurately. Because processes in SLNs regulate anti-tumor immune responses, ... Full text Link to item Cite

Systematic review of combinations of targeted or immunotherapy in advanced solid tumors.

Journal article J Immunother Cancer · July 2021 With rapid advances in our understanding of cancer, there is an expanding number of potential novel combination therapies, including novel-novel combinations. Identifying which combinations are appropriate and in which subpopulations are among the most dif ... Full text Link to item Cite

Second-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆.

Journal article Ann Oncol · May 2021 BACKGROUND: Patients with relapsed small-cell lung cancer (SCLC) have few treatment options and dismal survival. Phase I/II data show activity of nivolumab in previously treated SCLC. PATIENTS AND METHODS: CheckMate 331 is a randomized, open-label, phase I ... Full text Link to item Cite

Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC-an Update From the PACIFIC Trial.

Journal article J Thorac Oncol · May 2021 INTRODUCTION: In the Phase 3, placebo-controlled PACIFIC trial of patients with unresectable, stage III NSCLC without disease progression after concurrent chemoradiotherapy, consolidative durvalumab was associated with significant improvements in the prima ... Full text Link to item Cite

Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable stage III non-small-cell lung cancer.

Journal article Future Oncol · April 2021 Aim: We retrospectively investigated the impact of tumor PD-L1 expression and prior chemoradiotherapy (CRT)-related variables on patient-reported outcomes (PROs) from PACIFIC. Patients & methods: PACIFIC was a Phase III study of durvalumab versus placebo a ... Full text Link to item Cite

A Gene Mutation Signature Predicting Immunotherapy Benefits in Patients With NSCLC.

Journal article J Thorac Oncol · March 2021 INTRODUCTION: Identification of patients who can benefit from immune checkpoint blockade (ICB) therapy is key for improved clinical outcome. Recently, U.S. Food and Drug Administration approved tumor mutational burden (TMB) high (TMB-H or TMB ≥ 10) as a bi ... Full text Link to item Cite

Five-Year Outcomes From the Randomized, Phase III Trials CheckMate 017 and 057: Nivolumab Versus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer.

Journal article J Clin Oncol · March 1, 2021 PURPOSE: Immunotherapy has revolutionized the treatment of advanced non-small-cell lung cancer (NSCLC). In two phase III trials (CheckMate 017 and CheckMate 057), nivolumab showed an improvement in overall survival (OS) and favorable safety versus docetaxe ... Full text Link to item Cite

Prospective Single-Arm Phase 1 and 2 Study: Ipilimumab and Nivolumab With Thoracic Radiation Therapy After Platinum Chemotherapy in Extensive-Stage Small Cell Lung Cancer.

Journal article Int J Radiat Oncol Biol Phys · February 1, 2021 PURPOSE: Consolidative thoracic radiation therapy (TRT) has been shown to improve outcomes for patients with extensive stage small cell lung cancer. We hypothesized that the addition of ipilimumab (IPI) and nivolumab (NIVO) after TRT would improve outcomes ... Full text Link to item Cite

First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial.

Journal article Lancet · January 30, 2021 BACKGROUND: Approved systemic treatments for malignant pleural mesothelioma (MPM) have been limited to chemotherapy regimens that have moderate survival benefit with poor outcomes. Nivolumab plus ipilimumab has shown clinical benefit in other tumour types, ... Full text Link to item Cite

Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).

Journal article Lung Cancer · January 2021 INTRODUCTION: The PACIFIC trial demonstrated that durvalumab significantly improved progression-free and overall survival (PFS/OS), versus placebo, in patients with Stage III NSCLC and stable or responding disease following concurrent, platinum-based chemo ... Full text Link to item Cite

Sirt2 Inhibition Enhances Metabolic Fitness and Effector Functions of Tumor-Reactive T Cells.

Journal article Cell Metab · September 1, 2020 Dysregulated metabolism is a key driver of maladaptive tumor-reactive T lymphocytes within the tumor microenvironment. Actionable targets that rescue the effector activity of antitumor T cells remain elusive. Here, we report that the Sirtuin-2 (Sirt2) NAD+ ... Full text Link to item Cite

Breaking the Impasse: Advances in Treatment of Small Cell Lung Cancer.

Journal article Clin Chest Med · June 2020 Small cell lung cancer (SCLC) is an aggressive malignancy and carries a poor prognosis with limited effective treatments in the advanced setting. SCLC is characterized by a high tumor mutation burden and alterations in Notch signaling and DNA damage repair ... Full text Link to item Cite

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial.

Journal article Ann Oncol · June 2020 BACKGROUND: In the PACIFIC trial, durvalumab significantly improved progression-free and overall survival (PFS/OS) versus placebo, with manageable safety, in unresectable, stage III non-small-cell lung cancer (NSCLC) patients without progression after chem ... Full text Link to item Cite

Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial.

Journal article JAMA Oncol · May 1, 2020 IMPORTANCE: Checkpoint inhibitors targeting programmed cell death 1 or its ligand (PD-L1) as monotherapies or in combination with anti-cytotoxic T-lymphocyte-associated antigen 4 have shown clinical activity in patients with metastatic non-small cell lung ... Full text Link to item Cite

The immunotherapeutic landscape in non-small cell lung cancer and its surgical horizons.

Journal article J Thorac Cardiovasc Surg · April 2020 Lung cancer continues to be a leading cause of cancer-related death worldwide. Despite tremendous advances in surgical technique, chemotherapy regimens, radiation, and targeted therapies, survival is <50% at 5 years. Immunotherapy, specifically immune chec ... Full text Link to item Cite

Nivolumab Monotherapy and Nivolumab Plus Ipilimumab in Recurrent Small Cell Lung Cancer: Results From the CheckMate 032 Randomized Cohort.

Journal article J Thorac Oncol · March 2020 INTRODUCTION: Nivolumab monotherapy is approved in the United States for third-line or later metastatic small cell lung cancer based on pooled data from nonrandomized and randomized cohorts of the multicenter, open-label, phase 1/2 trial of nivolumab ± ipi ... Full text Link to item Cite

Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC-Update from PACIFIC.

Journal article J Thorac Oncol · February 2020 INTRODUCTION: In the phase 3 PACIFIC study of patients with unresectable stage III NSCLC without progression after chemoradiotherapy, durvalumab demonstrated significant improvements versus placebo in the primary end points of progression-free survival (ha ... Full text Link to item Cite

A community-based lung cancer rapid tissue donation protocol provides high-quality drug-resistant specimens for proteogenomic analyses.

Journal article Cancer Med · January 2020 BACKGROUND: For the advancement of cancer research, the collection of tissue specimens from drug-resistant tumors after targeted therapy is crucial. Although patients with lung cancer are often provided targeted therapy, post-therapy specimens are not rout ... Full text Link to item Cite

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.

Journal article Lancet Oncol · December 2019 BACKGROUND: In the ongoing, phase 3 PACIFIC trial, durvalumab improved the primary endpoints of progression-free survival and overall survival compared with that for placebo, with similar safety, in patients with unresectable, stage III non-small-cell lung ... Full text Link to item Cite

Phase I/Ib Study of Pembrolizumab Plus Vorinostat in Advanced/Metastatic Non-Small Cell Lung Cancer.

Journal article Clin Cancer Res · November 15, 2019 PURPOSE: Histone deacetylase inhibitors (HDACi) enhance tumor immunogenicity through several mechanisms and may improve response to immune checkpoint inhibitors (ICIs). In a phase I/Ib trial, we tested the oral HDACi vorinostat combined with the programmed ... Full text Link to item Cite

Five-Year Survival and Correlates Among Patients With Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated With Nivolumab.

Journal article JAMA Oncol · October 1, 2019 IMPORTANCE: Nivolumab, a monoclonal antibody that inhibits programmed cell death 1, is approved by the US Food and Drug Administration for treating advanced melanoma, renal cell carcinoma (RCC), non-small cell lung cancer (NSCLC), and other malignancies. D ... Full text Link to item Cite

Clinical Response of Live-Attenuated, Listeria monocytogenes Expressing Mesothelin (CRS-207) with Chemotherapy in Patients with Malignant Pleural Mesothelioma.

Journal article Clin Cancer Res · October 1, 2019 PURPOSE: Malignant pleural mesothelioma (MPM) is an aggressive cancer associated with poor prognosis. CRS-207 is a live-attenuated Listeria monocytogenes engineered to express mesothelin, a tumor-associated antigen highly expressed in MPM. CRS-207 induces ... Full text Link to item Cite

Four-year survival with nivolumab in patients with previously treated advanced non-small-cell lung cancer: a pooled analysis.

Journal article Lancet Oncol · October 2019 BACKGROUND: Phase 3 clinical data has shown higher proportions of patients with objective response, longer response duration, and longer overall survival with nivolumab versus docetaxel in patients with previously treated advanced non-small-cell lung cance ... Full text Link to item Cite

Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC.

Journal article J Thorac Oncol · October 2019 INTRODUCTION: Durvalumab is a selective, high-affinity human immunoglobulin G1 monoclonal antibody that blocks programmed cell death ligand 1 (PD-L1) binding to programmed death 1. Here we report safety and clinical activity in the NSCLC cohort of a phase ... Full text Link to item Cite

The NKG2A immune checkpoint - a new direction in cancer immunotherapy.

Journal article Nat Rev Clin Oncol · May 2019 Full text Link to item Cite

Oncolytic virotherapy for small-cell lung cancer induces immune infiltration and prolongs survival.

Journal article J Clin Invest · April 29, 2019 Oncolytic virotherapy has been proposed as an ablative and immunostimulatory treatment strategy for solid tumors that are resistant to immunotherapy alone; however, there is a need to optimize host immune activation using preclinical immunocompetent models ... Full text Link to item Cite

Phase 1 trial of dasatinib combined with afatinib for epidermal growth factor receptor- (EGFR-) mutated lung cancer with acquired tyrosine kinase inhibitor (TKI) resistance.

Journal article Br J Cancer · April 2019 BACKGROUND: Bypass activation of Src family kinases can confer resistance to EGFR tyrosine kinase inhibitors (TKIs) based on preclinical models. We prospectively assessed the safety and clinical activity of dasatinib and afatinib in combination for patient ... Full text Link to item Cite

Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs platinum-based chemotherapy (CT) based on clinical characteristics in patients with metastatic (m) NSCLC: Results from MYSTIC.

Journal article Ann Oncol · April 2019 Full text Link to item Cite

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer. Reply.

Journal article N Engl J Med · March 7, 2019 Full text Link to item Cite

Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.

Journal article Eur J Cancer · March 2019 INTRODUCTION: Durvalumab selectively blocks programmed cell death ligand-1 (PD-L1) binding to programmed cell death-1. Encouraging clinical activity and manageable safety were reported in urothelial carcinoma, non-small-cell lung cancer (NSCLC), hepatocell ... Full text Link to item Cite

Randomized-controlled phase II trial of salvage chemotherapy after immunization with a TP53-transfected dendritic cell-based vaccine (Ad.p53-DC) in patients with recurrent small cell lung cancer.

Journal article Cancer Immunol Immunother · March 2019 Small cell lung cancer TP53 mutations lead to expression of tumor antigens that elicits specific cytotoxic T-cell immune responses. In this phase II study, dendritic cells transfected with wild-type TP53 (vaccine) were administered to patients with extensi ... Full text Link to item Cite

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

Journal article Cancer Cell · February 11, 2019 Full text Link to item Cite

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032.

Journal article J Thorac Oncol · February 2019 INTRODUCTION: For patients with recurrent SCLC, topotecan remains the only approved second-line treatment, and the outcomes are poor. CheckMate 032 is a phase 1/2, multicenter, open-label study of nivolumab or nivolumab plus ipilimumab in SCLC or other adv ... Full text Link to item Cite

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC.

Journal article The New England journal of medicine · December 2018 BackgroundAn earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression-free survival, as compared with placebo, among patients with stage III, unresectable non-small-cell lung cancer (NSCLC) who did not have ... Full text Cite

A phase I/randomized phase II study of GM.CD40L vaccine in combination with CCL21 in patients with advanced lung adenocarcinoma.

Journal article Cancer Immunol Immunother · December 2018 The GM.CD40L vaccine, which recruits and activates dendritic cells, migrates to lymph nodes, activating T cells and leading to systemic tumor cell killing. When combined with the CCL21 chemokine, which recruits T cells and enhances T-cell responses, additi ... Full text Link to item Cite

Clinical associations of mucin 1 in human lung cancer and precancerous lesions.

Journal article Oncotarget · November 2, 2018 Mucin 1 (MUC1) is a cell membrane glycoprotein overexpressed in non-small cell lung cancer (NSCLC) and has been implicated in carcinogenesis of premalignant lung lesions. Thus, MUC1 has been a target of interest for vaccine strategies for lung cancer treat ... Full text Link to item Cite

Evaluation of combined anti-PD-1 immunotherapy and radiation therapy in a preclinical mouse model of pneumonitis and fibrosis.

Journal article J Thorac Dis · November 2018 Full text Link to item Cite

Reply to Dickhoff et al. from authors of 'Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer'.

Journal article Lung Cancer · October 2018 Full text Link to item Cite

Nivolumab Plus Erlotinib in Patients With EGFR-Mutant Advanced NSCLC.

Journal article J Thorac Oncol · September 2018 INTRODUCTION: This phase I study evaluated nivolumab combined with erlotinib in patients with advanced EGFR-mutant NSCLC. METHODS: Patients with advanced EGFR-mutant NSCLC who were EGFR tyrosine kinase inhibitor (TKI)-naive or TKI-treated but had not recei ... Full text Link to item Cite

Safety and clinical activity of atezolizumab monotherapy in metastatic non-small-cell lung cancer: final results from a phase I study.

Journal article European journal of cancer (Oxford, England : 1990) · September 2018 IntroductionAtezolizumab, an anti-programmed death-ligand 1 (PD-L1) antibody, inhibits PD-L1:PD-1 and PD-L1:B7.1 interactions, restoring anticancer immunity. Here, we report final analyses from the non-small-cell lung cancer (NSCLC) cohort of the ... Full text Cite

Induction chemoradiotherapy versus chemotherapy alone for superior sulcus lung cancer.

Journal article Lung Cancer · August 2018 OBJECTIVES: Although treatment of superior sulcus tumors with induction chemoradiotherapy (CRT) followed by surgery employed in the Intergroup INT-0160 trial is widely adopted as a standard of care, there may be significant associated morbidity and mortali ... Full text Link to item Cite

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).

Journal article Journal for immunotherapy of cancer · July 2018 Lung cancer is the leading cause of cancer-related mortality worldwide, with non-small cell lung cancer (NSCLC) accounting for over 85% of all cases. Until recently, chemotherapy - characterized by some benefit but only rare durable responses - was the onl ... Full text Cite

The current understanding of the endocrine effects from immune checkpoint inhibitors and recommendations for management

Journal article Jnci Cancer Spectrum · July 1, 2018 Clinical trials in the past decade have established the antitumor effects of immune checkpoint inhibition as a revolutionary treatment for cancer. Namely, blocking antibodies to cytotoxic T-lymphocyte antigen 4 and programmed death 1 or its ligand have rea ... Full text Cite

Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study.

Journal article J Clin Oncol · June 10, 2018 Purpose In two phase III studies, nivolumab, a programmed death-1 (PD-1) inhibitor antibody, improved overall survival (OS) versus docetaxel in pretreated advanced non-small-cell lung cancer (NSCLC). We report 5-year follow-up results from an early phase I ... Full text Link to item Cite

Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer.

Journal article Cancer Cell · May 14, 2018 Durable responses and encouraging survival have been demonstrated with immune checkpoint inhibitors in small-cell lung cancer (SCLC), but predictive markers are unknown. We used whole exome sequencing to evaluate the impact of tumor mutational burden on ef ... Full text Link to item Cite

Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer.

Journal article Cancer Cell · May 14, 2018 Combination immune checkpoint blockade has demonstrated promising benefit in lung cancer, but predictors of response to combination therapy are unknown. Using whole-exome sequencing to examine non-small-cell lung cancer (NSCLC) treated with PD-1 plus CTLA- ... Full text Link to item Cite

Nivolumab versus docetaxel in previously treated advanced non-small-cell lung cancer (CheckMate 017 and CheckMate 057): 3-year update and outcomes in patients with liver metastases.

Journal article Ann Oncol · April 1, 2018 BACKGROUND: Long-term data with immune checkpoint inhibitors in non-small-cell lung cancer (NSCLC) are limited. Two phase III trials demonstrated improved overall survival (OS) and a favorable safety profile with the anti-programmed death-1 antibody nivolu ... Full text Link to item Cite

Patient, caregiver and physician perspectives on participating in a thoracic rapid tissue donation program.

Journal article Patient Educ Couns · April 2018 OBJECTIVE: The collection of posthumous tissue from advanced stage lung cancer patients is beneficial to medical science. Recruiting living patients to a Rapid Tissue Donation Program (RTD) poses several psychosocial challenges and little is known about pe ... Full text Link to item Cite

PD-L1 Antibodies for EBV-Positive Gastric Cancer, Going Beyond PD-L1 Expression and Microsatellite Instability.

Journal article J Natl Cancer Inst · March 1, 2018 Full text Link to item Cite

Durvalumab in Stage III Non-Small-Cell Lung Cancer.

Journal article N Engl J Med · March 1, 2018 Full text Link to item Cite

A phase-1/2 study of adenovirus-p53 transduced dendritic cell vaccine in combination with indoximod in metastatic solid tumors and invasive breast cancer.

Journal article Oncotarget · February 9, 2018 BACKGROUND: Indoleamine 2, 3-dioxygenase is an enzyme that causes immunosuppression in tumors. Indoximod inhibits the indoleamine 2, 3-dioxygenase pathway and enhances immunologic responses to dendritic cell (DC) vaccines preclinically. Adenovirus p53 (Ad. ... Full text Link to item Cite

Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer.

Journal article Cancer Manag Res · 2018 Lung cancer is the most common cancer worldwide and the most common cause of cancer-related death. Non-small-cell lung cancer comprises ~87% of newly diagnosed cases of lung cancer, and nearly one-third of these patients have stage III disease. Despite imp ... Full text Link to item Cite

Tumor immunology and immune checkpoint inhibitors in non-small cell lung cancer

Journal article Tuberculosis and Respiratory Diseases · January 1, 2018 Lung cancer is one of the most commonly diagnosed cancers and the leading cause of cancer-related deaths worldwide. Although progress in the treatment of advanced non-small cell lung cancer (NSCLC) has been made over the past decade, the 5-year survival ra ... Full text Cite

Nivolumab Versus Docetaxel in Previously Treated Patients With Advanced Non-Small-Cell Lung Cancer: Two-Year Outcomes From Two Randomized, Open-Label, Phase III Trials (CheckMate 017 and CheckMate 057).

Journal article J Clin Oncol · December 10, 2017 Purpose Nivolumab, a programmed death-1 inhibitor, prolonged overall survival compared with docetaxel in two independent phase III studies in previously treated patients with advanced squamous (CheckMate 017; ClinicalTrials.gov identifier: NCT01642004) or ... Full text Link to item Cite

Retrospective analysis of technical success rate and procedure-related complications of 867 percutaneous CT-guided needle biopsies of lung lesions.

Journal article Clin Radiol · December 2017 AIM: To investigate the technical success rate and procedure-related complications of computed tomography (CT)-guided needle biopsy of lung lesions and to identify the factors that are correlated with the occurrence of procedure-related complications. MATE ... Full text Link to item Cite

Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Journal article N Engl J Med · November 16, 2017 BACKGROUND: Most patients with locally advanced, unresectable, non-small-cell lung cancer (NSCLC) have disease progression despite definitive chemoradiotherapy (chemotherapy plus concurrent radiation therapy). This phase 3 study compared the anti-programme ... Full text Link to item Cite

PACIFIC: A double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC

Journal article Annals of Oncology · November 1, 2017 Full text Cite

A Bayesian pick-the-winner design in a randomized phase II clinical trial.

Journal article Oncotarget · October 24, 2017 PURPOSE: Many phase II clinical trials evaluate unique experimental drugs/combinations through multi-arm design to expedite the screening process (early termination of ineffective drugs) and to identify the most effective drug (pick the winner) to warrant ... Full text Link to item Cite

Radiotherapy Rescue of a Nivolumab-Refractory Immune Response in a Patient with PD-L1-Negative Metastatic Squamous Cell Carcinoma of the Lung.

Journal article J Thorac Oncol · September 2017 Full text Link to item Cite

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial.

Journal article Lancet Oncol · September 2017 BACKGROUND: New therapeutic strategies for malignant mesothelioma are urgently needed. In the DETERMINE study, we investigated the effects of the cytotoxic-T-lymphocyte-associated antigen 4 (CTLA-4) monoclonal antibody tremelimumab in patients with previou ... Full text Link to item Cite

Progressive hypoventilation due to mixed CD8+ and CD4+ lymphocytic polymyositis following tremelimumab - durvalumab treatment.

Journal article J Immunother Cancer · July 18, 2017 BACKGROUND: The combination of CTLA-4 and PD-L1 inhibitors has a manageable adverse effect profile, although rare immune-related adverse events (irAE) can occur. CASE PRESENTATION: We describe an autoimmune polymyositis following a partial response to comb ... Full text Link to item Cite

A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment.

Journal article Neoplasia (New York, N.Y.) · July 2017 BackgroundTherapeutic strategies targeting immune checkpoint proteins have led to significant responses in patients with various tumor types. The success of these studies has led to the development of various antibodies/inhibitors for the differen ... Full text Cite

Outcomes targeting the PD-1/PD-L1 axis in conjunction with stereotactic radiation for patients with non-small cell lung cancer brain metastases.

Journal article J Neurooncol · June 2017 Anti-PD-1/PD-L1 therapies have demonstrated activity in patients with advanced stage non-small cell lung cancer (NSCLC). However, little is known about the safety and feasibility of patients receiving anti-PD-1/PD-L1 therapy and stereotactic radiation for ... Full text Link to item Cite

PD-1 checkpoint blockade alone or combined PD-1 and CTLA-4 blockade as immunotherapy for lung cancer?

Journal article Expert Opin Biol Ther · March 2017 Signaling through T-cell surface, an immune checkpoint protein such as PD-1 or CTLA-4 helps dampen or terminate unwanted immune responses. Blocking a single immune checkpoint or multiple checkpoints simultaneously can generate anti-tumor activity against a ... Full text Link to item Cite

Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study.

Journal article Lancet Oncol · January 2017 BACKGROUND: Nivolumab has shown improved survival in the treatment of advanced non-small-cell lung cancer (NSCLC) previously treated with chemotherapy. We assessed the safety and activity of combination nivolumab plus ipilimumab as first-line therapy for N ... Full text Link to item Cite

Reply to: Comment on 'Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung'.

Journal article Br J Cancer · January 2017 Full text Link to item Cite

Safety, pharmacokinetics, and pharmacodynamics of oral omaveloxolone (RTA 408), a synthetic triterpenoid, in a first-in-human trial of patients with advanced solid tumors.

Journal article Onco Targets Ther · 2017 BACKGROUND: Omaveloxolone is a semisynthetic oleanane triterpenoid that potently activates Nrf2 with subsequent antioxidant function. We conducted a first-in-human Phase I clinical trial (NCT02029729) with the primary objectives to determine the appropriat ... Full text Link to item Cite

Strategies for power calculations in predictive biomarker studies in survival data.

Journal article Oncotarget · December 6, 2016 PURPOSE: Biomarkers and genomic signatures represent potentially predictive tools for precision medicine. Validation of predictive biomarkers in prospective or retrospective studies requires statistical justification of power and sample size. However, the ... Full text Link to item Cite

Clinical activity, safety and predictive biomarkers results from a phase Ia atezolizumab (atezo) trial in extensive-stage small cell lung cancer (ES-SCLC)

Journal article Annals of Oncology · October 1, 2016 Full text Cite

Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort

Journal article Annals of Oncology · October 1, 2016 Full text Cite

Nivolumab in Combination With Platinum-Based Doublet Chemotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

Journal article J Clin Oncol · September 1, 2016 PURPOSE: Nivolumab, a fully human immunoglobulin G4 programmed death-1 immune checkpoint inhibitor antibody, has demonstrated improved survival in previously treated patients with advanced non-small-cell lung cancer (NSCLC). CheckMate 012, a phase I, multi ... Full text Link to item Cite

Nivolumab Monotherapy for First-Line Treatment of Advanced Non-Small-Cell Lung Cancer.

Journal article J Clin Oncol · September 1, 2016 PURPOSE: Nivolumab, a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, has demonstrated improved survival over docetaxel in previously treated advanced non-small-cell lung cancer (NSCLC). First-line monotherapy with nivolumab for advanced NS ... Full text Link to item Cite

The safety and efficacy of nivolumab in advanced (metastatic) non-small cell lung cancer.

Journal article Expert review of anticancer therapy · September 2016 IntroductionAdvanced non-small cell lung cancer (NSCLC) is a challenging oncological problem. Following standard initial therapy, disease progression will typically develop. Patients with relapsed or refractory disease are left with limited treatm ... Full text Cite

HDAC Inhibitors Enhance T-Cell Chemokine Expression and Augment Response to PD-1 Immunotherapy in Lung Adenocarcinoma.

Journal article Clin Cancer Res · August 15, 2016 PURPOSE: A significant limitation of checkpoint blockade immunotherapy is the relatively low response rate (e.g., ∼20% with PD-1 blockade in lung cancer). In this study, we tested whether strategies that increase T-cell infiltration to tumors can be effica ... Full text Link to item Cite

Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung.

Journal article Br J Cancer · August 9, 2016 BACKGROUND: Although ∼20% of human cancers are caused by microorganisms, only suspicion exists for a microbial cause of lung cancer. Potential infectious agents were investigated in non-small cell lung cancer (NSCLC) and non-neoplastic lung. METHODS: Seven ... Full text Link to item Cite

Moving beyond monotherapy in the immunotherapeutic arena: prospects for combination therapies in lung cancer.

Journal article Clin Adv Hematol Oncol · August 2016 Link to item Cite

Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial.

Journal article Lancet Oncol · July 2016 BACKGROUND: Treatments for small-cell lung cancer (SCLC) after failure of platinum-based chemotherapy are limited. We assessed safety and activity of nivolumab and nivolumab plus ipilimumab in patients with SCLC who progressed after one or more previous re ... Full text Link to item Cite

Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.

Journal article Oncogene · June 16, 2016 While mutations in the KRAS oncogene are among the most prevalent in human cancer, there are few successful treatments to target these tumors. It is also likely that heterogeneity in KRAS-mutant tumor biology significantly contributes to the response to th ... Full text Link to item Cite

A phase I study of indoximod in patients with advanced malignancies.

Journal article Oncotarget · April 19, 2016 PURPOSE: Indoximod is an oral inhibitor of the indoleamine 2,3-dioxygenase pathway, which causes tumor-mediated immunosuppression. Primary endpoints were maximum tolerated dose (MTD) and toxicity for indoximod in patients with advanced solid tumors. Second ... Full text Link to item Cite

The anti-fibrotic agent pirfenidone synergizes with cisplatin in killing tumor cells and cancer-associated fibroblasts.

Journal article BMC Cancer · March 2, 2016 BACKGROUND: Anti-fibrotic drugs such as pirfenidone have been developed for the treatment of idiopathic pulmonary fibrosis. Because activated fibroblasts in inflammatory conditions have similar characteristics as cancer-associated fibroblasts (CAFs) and CA ... Full text Link to item Cite

Safety and antitumour activity of durvalumab plus tremelimumab in non-small cell lung cancer: a multicentre, phase 1b study.

Journal article Lancet Oncol · March 2016 BACKGROUND: PD-L1 and CTLA-4 immune checkpoints inhibit antitumour T-cell activity. Combination treatment with the anti-PD-L1 antibody durvalumab and the anti-CTLA-4 antibody tremelimumab might provide greater antitumour activity than either drug alone. We ... Full text Link to item Cite

Immunotherapy: Beyond Anti-PD-1 and Anti-PD-L1 Therapies.

Journal article Am Soc Clin Oncol Educ Book · 2016 Advanced-stage non-small cell lung cancer (NSCLC) and small cell lung cancer are cancers in which chemotherapy produces a survival benefit, although it is small. We now know that anti-PD-1/PD-L1 has substantial clinical activity in both of these diseases, ... Full text Link to item Cite

A GM-CSF and CD40L bystander vaccine is effective in a murine breast cancer model

Journal article Breast Cancer Targets and Therapy · December 15, 2015 Background: There is increasing interest in using cancer vaccines to treat breast cancer patients in the adjuvant setting to prevent recurrence in high risk situations or in combination with other immunomodulators in the advanced setting. Current peptide v ... Full text Cite

Propelling immunotherapy combinations into the clinic

Journal article Oncology United States · December 15, 2015 This review summarizes promising new targets and immunotherapy combination strategies currently under clinical development. ... Cite

Propelling Immunotherapy Combinations Into the Clinic.

Journal article Oncology (Williston Park) · December 2015 Immune checkpoint inhibitors produce durable long-term survival in some patients with advanced melanoma and lung cancer. Better immune targets and combination strategies can harness the immune system by supporting the three elements of a successful T-cell ... Link to item Cite

Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer.

Journal article N Engl J Med · October 22, 2015 BACKGROUND: Nivolumab, a fully human IgG4 programmed death 1 (PD-1) immune-checkpoint-inhibitor antibody, disrupts PD-1-mediated signaling and may restore antitumor immunity. METHODS: In this randomized, open-label, international phase 3 study, we assigned ... Full text Link to item Cite

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.

Journal article N Engl J Med · July 9, 2015 BACKGROUND: Patients with advanced squamous-cell non-small-cell lung cancer (NSCLC) who have disease progression during or after first-line chemotherapy have limited treatment options. This randomized, open-label, international, phase 3 study evaluated the ... Full text Link to item Cite

Charting Immune Signaling Proteomes En Route to New Therapeutic Strategies.

Journal article Cancer Immunol Res · July 2015 The activation state of an antitumor effector T cell in a tumor depends on the sum of all stimulatory signals and inhibitory signals that it receives in the tumor microenvironment. Accumulating data address the increasing complexity of these signals produc ... Full text Link to item Cite

Non-Small-Cell Lung Cancer: Role of the Immune System and Potential for Immunotherapy.

Journal article J Thorac Oncol · July 2015 As the leading cause of cancer death worldwide, lung cancer continues to impose a major burden on healthcare systems and cause significant challenges for clinicians and patients. Most patients present with advanced disease at the time of diagnosis and have ... Full text Link to item Cite

Overall Survival and Long-Term Safety of Nivolumab (Anti-Programmed Death 1 Antibody, BMS-936558, ONO-4538) in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer.

Journal article J Clin Oncol · June 20, 2015 PURPOSE: Programmed death 1 is an immune checkpoint that suppresses antitumor immunity. Nivolumab, a fully human immunoglobulin G4 programmed death 1 immune checkpoint inhibitor antibody, was active and generally well tolerated in patients with advanced so ... Full text Link to item Cite

Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.

Journal article Lancet Oncol · March 2015 BACKGROUND: Patients with squamous non-small-cell lung cancer that is refractory to multiple treatments have poor outcomes. We assessed the activity of nivolumab, a fully human IgG4 PD-1 immune checkpoint inhibitor antibody, for patients with advanced, ref ... Full text Link to item Cite

Long-term clinical responses of neoadjuvant dendritic cell infusions and radiation in soft tissue sarcoma

Journal article Sarcoma · January 1, 2015 Purpose. Patients with large >5 cm, high-grade resectable soft tissue sarcomas (STS) have the highest risk of distant metastases. Previously we have shown that dendritic cell (DC) based vaccines show consistent immune responses. Methods. This was a Phase I ... Full text Cite

Immuno-oncology combinations: a review of clinical experience and future prospects.

Journal article Clin Cancer Res · December 15, 2014 Immuno-oncology is an evolving treatment modality that includes immunotherapies designed to harness the patient's own immune system. This approach is being studied for its potential to improve long-term survival across multiple tumor types. It is now impor ... Full text Link to item Cite

Phase 2 study of concurrent cetuximab plus definitive thoracic radiation therapy followed by consolidation docetaxel plus cetuximab in poor prognosis or elderly patients with locally advanced non-small cell lung cancer.

Journal article Int J Radiat Oncol Biol Phys · November 15, 2014 BACKGROUND: Recursive partitioning analysis has shown that Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) ≥2, male sex, and age ≥70 years are prognostic of poor outcome in locally advanced non-small cell lung cancer (LA-NSCLC) patients. ... Full text Link to item Cite

Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression.

Journal article Nat Commun · October 28, 2014 Immunosuppression of tumour-infiltrating lymphocytes (TIL) is a common feature of advanced cancer, but its biological basis has remained obscure. We demonstrate here a molecular link between epithelial-to-mesenchymal transition (EMT) and CD8(+) TIL immunos ... Full text Link to item Cite

A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors.

Journal article Oncotarget · September 30, 2014 BACKGROUND: Indoleamine 2,3-dioxygenase (IDO) is an enzyme that tumors use to create a state of immunosuppression. Indoximod is an IDO pathway inhibitor. Preclinical studies demonstrated that indoximod combined with chemotherapy was synergistic in a mouse ... Full text Link to item Cite

ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.

Journal article J Clin Invest · June 2014 Myeloid-derived suppressor cells (MDSCs) dampen the immune response thorough inhibition of T cell activation and proliferation and often are expanded in pathological conditions. Here, we studied the fate of MDSCs in cancer. Unexpectedly, MDSCs had lower vi ... Full text Link to item Cite

PD-L1 expression is increased in a subset of basal type breast cancer cells.

Journal article PLoS One · 2014 BACKGROUND: Tumor cells express programmed death ligand 1 (PD-L1) and is a key immune evasion mechanism. PD-L1 expression in multiple breast cancer cell lines was evaluated to identify intrinsic differences that affect their potential for immune evasion. M ... Full text Link to item Cite

Building a long distance training program to enhance clinical cancer research capacity in Puerto Rico.

Journal article Rev Recent Clin Trials · 2014 Barriers persist in the development and delivery of effective cancer therapies to under-represented minority populations. In Puerto Rico, cancer is the second leading cause of death, yet cancer research awareness and training opportunities remain somewhat ... Full text Link to item Cite

Immunotherapy in lung cancer: "b7-bombers" and other new developments.

Journal article Semin Respir Crit Care Med · December 2013 Several recent immunotherapy agents have exhibited exceptional activity, and their eventual approval for use in lung cancer appears plausible. The immune checkpoint proteins, such as the B7 superfamily, are becoming increasingly relevant targets for therap ... Full text Link to item Cite

Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinoma.

Journal article J Immunother · October 2013 We created a vaccine in which irradiated allogeneic lung adenocarcinoma cells are combined with a bystander K562 cell line transfected with hCD40L and hGM-CSF. By recruiting and activating dendritic cells, we hypothesized that the vaccine would induce tumo ... Full text Link to item Cite

A new role for NFκB in immunosurveillance and its implications for cancer immunotherapy.

Journal article Oncoimmunology · October 1, 2013 The activation of NFκB in the tumor microenvironment is associated with inflammatory responses that promote disease progression. We have recently found that the activation of NFκB in the tumor also regulates T cell-mediated immune responses, hence actively ... Full text Link to item Cite

The bottleneck effect in lung cancer clinical trials.

Journal article J Cancer Educ · September 2013 Clinical trials provide the most promising way to improve treatment outcomes in cancer. This study examined the rate at which eligible patients with lung cancer, at a National Cancer Institute-designated cancer center in the South, were offered a clinical ... Full text Link to item Cite

Antagonism of adenosine A2A receptor expressed by lung adenocarcinoma tumor cells and cancer associated fibroblasts inhibits their growth.

Journal article Cancer Biol Ther · September 2013 Recently it has become clear that the cost associated with the Warburg effect, which is inefficient production of ATP, is offset by selective advantages that are produced by resultant intracellular metabolic alterations. In fact tumors may be addicted to t ... Full text Link to item Cite

Randomized international phase III trial of ERCC1 and RRM1 expression-based chemotherapy versus gemcitabine/carboplatin in advanced non-small-cell lung cancer.

Journal article Journal of clinical oncology : official journal of the American Society of Clinical Oncology · July 2013 PurposeWe assessed whether chemotherapy selection based on in situ ERCC1 and RRM1 protein levels would improve survival in patients with advanced non-small-cell lung cancer (NSCLC).Patients and methodsEligible patients were randomly assig ... Full text Cite

Lung tumor NF-κB signaling promotes T cell-mediated immune surveillance.

Journal article J Clin Invest · June 2013 NF-κB is constitutively activated in many cancer types and is a potential key mediator of tumor-associated inflammation, tumor growth, and metastasis. We investigated the role of cancer cell NF-κB activity in T cell-mediated antitumor responses. In tumors ... Full text Link to item Cite

Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer.

Journal article Cancer immunology, immunotherapy : CII · May 2013 Myeloid-derived suppressor cells (MDSC) are one of the major factors limiting the efficacy of immune therapy. In a clinical trial of patients with extensive stage small cell lung cancer (SCLC), we tested the possibility that targeting MDSC can improve the ... Full text Cite

Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry.

Journal article Cancer Immunol Immunother · May 2013 INTRODUCTION: The immunosuppressive enzyme, indoleamine 2,3 dioxygenase (IDO), is overexpressed in many different tumor types including breast cancer. IDO inhibitors synergize with chemotherapy in breast cancer murine models. Characterizing IDO expression ... Full text Link to item Cite

Adapting to the brave new world of lung cancer treatment.

Journal article Oncology (Williston Park) · May 2013 Link to item Cite

Indoleamine 2,3-dioxygenase activity and clinical outcome following induction chemotherapy and concurrent chemoradiation in Stage III non-small cell lung cancer.

Journal article Oncoimmunology · March 1, 2013 Indoleamine 2,3-dioxygenase (IDO) has recently been proposed to account for tumor-induced immunosuppression by influencing the conversion of tryptophan (Trp) into kynurenine (Kyn). The objective of our study was to correlate IDO activity with disease outco ... Full text Link to item Cite

Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer.

Journal article Nat Immunol · March 2013 Two major populations of myeloid-derived suppressor cells (MDSCs), monocytic MDSCs (M-MDSCs) and polymorphonuclear MDSCs (PMN-MDSCs) regulate immune responses in cancer and other pathologic conditions. Under physiologic conditions, Ly6C(hi)Ly6G(-) inflamma ... Full text Link to item Cite

Suspected methotrexate toxicity from omeprazole: a case review of carboxypeptidase G2 use in a methotrexate-experienced patient with methotrexate toxicity and a review of the literature.

Journal article J Pharm Pract · August 2012 We report a case of methotrexate toxicity potentially induced by a drug interaction between methotrexate and omeprazole in a 25-year-old man with osteosarcoma. The patient was placed on omeprazole after his first cycle of high-dose methotrexate for stress ... Full text Link to item Cite

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.

Journal article N Engl J Med · June 28, 2012 BACKGROUND: Blockade of programmed death 1 (PD-1), an inhibitory receptor expressed by T cells, can overcome immune resistance. We assessed the antitumor activity and safety of BMS-936558, an antibody that specifically blocks PD-1. METHODS: We enrolled pat ... Full text Link to item Cite

Preliminary indication of survival benefit from ERCC1 and RRM1-tailored chemotherapy in patients with advanced nonsmall cell lung cancer: evidence from an individual patient analysis.

Journal article Cancer · May 1, 2012 BACKGROUND: Excision repair cross complementing 1 (ERCC1) and ribonucleotide reductase M1 (RRM1) are molecular determinants that predict sensitivity or resistance to platinum agents and gemcitabine, respectively. Tailored therapy using these molecular dete ... Full text Link to item Cite

Serial assessment of lymphocytes and apoptosis in the prostate during coordinated intraprostatic dendritic cell injection and radiotherapy.

Journal article Immunotherapy · April 2012 Local radiotherapy plus intratumoral syngeneic dendritic cell injection can mediate apoptosis/cell death and immunological tumor eradication in murine models. A novel method of coordinated intraprostatic, autologous dendritic cell injection together with r ... Full text Link to item Cite

Cellular immunotherapy for soft tissue sarcomas.

Journal article Immunotherapy · March 2012 Soft tissue sarcomas are rare neoplasms, with approximately 9000 new cases in the USA every year. Unfortunately, during the past two decades, there has been little progress in the treatment of metastatic soft tissue sarcomas beyond the standard approaches ... Full text Link to item Cite

Combination of external beam radiotherapy (EBRT) with intratumoral injection of dendritic cells as neo-adjuvant treatment of high-risk soft tissue sarcoma patients.

Journal article Int J Radiat Oncol Biol Phys · February 1, 2012 PURPOSE: The goal of this study was to determine the effect of combination of intratumoral administration of dendritic cells (DC) and fractionated external beam radiation (EBRT) on tumor-specific immune responses in patients with soft-tissue sarcoma (STS). ... Full text Link to item Cite

Phase II study of sunitinib malate, a multitargeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on three prevalent histologies: leiomyosarcoma, liposarcoma and malignant fibrous histiocytoma.

Journal article Int J Cancer · October 15, 2011 Soft tissue sarcomas (STS) represent a diverse group of histologic subtypes with targetable molecular alterations, often treated as a single disease. Sunitinib malate is a multitargeted receptor tyrosine kinase inhibitor active in other solid tumors carryi ... Full text Link to item Cite

Paclitaxel and TRAIL synergize to kill paclitaxel-resistant small cell lung cancer cells through a caspase-independent mechanism mediated through AIF.

Journal article Anticancer Res · October 2011 BACKGROUND: Small cell lung cancer (SCLC) is the most aggressive form of lung cancer with poor disease outcome. The chemotherapeutic agent paclitaxel (PA) is commonly used as a second-line treatment in SCLC, but response rates are low. MATERIALS AND METHOD ... Link to item Cite

A CD117 and CD34 immunoreactive sarcoma masquerading as a gastrointestinal stromal tumor: diagnostic pitfalls of ancillary studies in sarcoma.

Journal article Cancer Control · July 2011 BACKGROUND: The immunohistochemical hallmarks of gastrointestinal stromal tumors (GISTs) are positivity for CD117 (c-kit) and CD34; however, CD117 is not specific for GISTs, and the list of CD117+ tumors/tissues is increasing. Also, MDM2 is known to be amp ... Full text Link to item Cite

Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors.

Journal article Cancer Biol Ther · November 15, 2010 BACKGROUND: Single-dose infusion of the agonistic anti-CD40 monoclonal antibody (mAb) CP-870,893 accomplishes immune activation and clinical responses in patients with advanced cancers, but repeat dosing of this agent has not been reported. RESULTS: Twenty ... Full text Link to item Cite

Changes in dendritic cell phenotype after a new high-dose weekly schedule of interleukin-2 therapy for kidney cancer and melanoma.

Journal article J Immunother · October 2010 High-dose intravenous interleukin-2 (IL-2) therapy (14 doses/course, 2 courses/cycle) for metastatic melanoma or kidney cancer induces infrequent, although major responses. In this trial, we evaluated a new schedule (dose of 600,000 IU/kg, 8 h between dose ... Full text Link to item Cite

Lipid accumulation and dendritic cell dysfunction in cancer.

Journal article Nat Med · August 2010 Dendritic cells (DCs), a type of professional antigen-presenting cells, are responsible for initiation and maintenance of immune responses. Here we report that a substantial proportion of DCs in tumor-bearing mice and people with cancer have high amounts o ... Full text Link to item Cite

INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect.

Journal article Expert Opin Biol Ther · June 2010 IMPORTANCE OF THE FIELD: Novel approaches are needed for patients with small cell lung cancer (SCLC), as response after relapse is poor with standard therapies. p53 gene mutations often occur, resulting in tumoral protein overexpression and allowing for th ... Full text Link to item Cite

Soft tissue sarcoma.

Journal article J Natl Compr Canc Netw · June 2010 Full text Link to item Cite

Chemotherapy enhances tumor cell susceptibility to CTL-mediated killing during cancer immunotherapy in mice.

Journal article J Clin Invest · April 2010 Cancer immunotherapy faces a serious challenge because of low clinical efficacy. Recently, a number of clinical studies have reported the serendipitous finding of high rates of objective clinical response when cancer vaccines are combined with chemotherapy ... Full text Link to item Cite

Systemic therapy for advanced hepatocellular carcinoma: past, present, and future.

Journal article Cancer Control · April 2010 BACKGROUND: Although approximately 80% of hepatocellular carcinoma (HCC) cases occur in developing countries, the incidence of HCC in Western countries is on the rise due to the impact of hepatitis C. Challenges in developing effective therapies include th ... Full text Link to item Cite

Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer.

Journal article Clin Cancer Res · March 15, 2010 PURPOSE: Myeloid-derived suppressor cells (MDSC) are one of the major factors responsible for immune suppression in cancer. Therefore, it would be important to identify effective therapeutic means to modulate these cells. EXPERIMENTAL DESIGN: We evaluated ... Full text Link to item Cite

Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer.

Journal article Journal of clinical oncology : official journal of the American Society of Clinical Oncology · March 2010 PurposeSrc family kinase (SFK) proteins are frequently activated in cancer and can coordinate tumor cell growth, survival, invasion, and angiogenesis. Given the importance of SFK signaling in cancer, known cooperation between SFK and epidermal gro ... Full text Cite

Thymidylate synthase 1 (TS1) in-situ protein expression predicts the survival of Ewing/PNET.

Journal article Fetal Pediatr Pathol · 2010 Thymidylate synthase (TS1), RRM1, and ERCC1, which are crucial for DNA synthesis and repair and have shown prognostic and predictive value in carcinomas, were investigated in Ewing/primitive neuroectodermal tumor (PNET). The tissue microarray consisting of ... Full text Link to item Cite

Indoleamine 2,3-dioxygenase: is it an immune suppressor?

Journal article Cancer J · 2010 This article covers what is currently known about the role of the enzyme indoleamine 2,3-dioxygenase (IDO) in cancer-related immunosuppression and the clinical research on IDO inhibitors. A PUBMED search was performed using the terms IDO, indoleamine 2,3-d ... Full text Link to item Cite

Hepatic portal venous gas in a patient with metastatic non-small cell lung cancer on bevacizumab therapy: a case report and review of the literature.

Journal article Cancer Chemother Pharmacol · December 2009 BACKGROUND: The presence of hepatic portal venous gas (HPVG) is a rare finding. It is most commonly caused by bowel necrosis and typically carries a grave prognosis. Bevacizumab has emerged as an effective standard therapy in the frontline management of ad ... Full text Link to item Cite

Phase I/II trial of tremelimumab in patients with metastatic melanoma.

Journal article J Clin Oncol · March 1, 2009 PURPOSE: Cytotoxic T lymphocyte-associated antigen 4 (CTLA4) blockade with tremelimumab (CP-675,206), a fully human anti-CTLA4 monoclonal antibody, was tolerated and demonstrated antitumor activity in a single dose, dose-escalation phase I trial in patient ... Full text Link to item Cite

Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin.

Journal article J Clin Oncol · November 10, 2008 PURPOSE: To determine the maximum-tolerated dose (MTD) and assess the safety, pharmacokinetics, and preliminary evidence of antitumor activity of YM155, a small-molecule inhibitor of survivin. PATIENTS AND METHODS: Patients with advanced solid malignancies ... Full text Link to item Cite

Clinical efficacy and predictive molecular markers of neoadjuvant gemcitabine and pemetrexed in resectable non-small cell lung cancer.

Journal article Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · October 2008 BackgroundA trial of neoadjuvant gemcitabine and pemetrexed (GP) chemotherapy in patients with resectable non-small cell lung cancer was conducted. The goal was to achieve a disease response rate of 50% and to determine if the expression levels of ... Full text Cite

Combined modality immunotherapy and chemotherapy: a new perspective.

Journal article Cancer Immunol Immunother · October 2008 The results of recent clinical trials have demonstrated that cancer vaccines continue to struggle to achieve tangible clinical benefits as monotherapy. Tumor-induced abnormalities in the immune system hamper anti-tumor T cell responses limiting the effecti ... Full text Link to item Cite

Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or older.

Journal article Cancer · May 1, 2008 BACKGROUND: This is a phase 2 study of chemotherapy-naive patients, 70 years of age or older, with nonsmall-cell lung cancer (NSCLC) who were treated with docetaxel and gefitinib. The primary endpoint was response rate (RR). Secondary endpoints were overal ... Full text Link to item Cite

Phase I/II study of atrasentan, an endothelin A receptor antagonist, in combination with paclitaxel and carboplatin as first-line therapy in advanced non-small cell lung cancer.

Journal article Clin Cancer Res · March 1, 2008 PURPOSE: Endothelins and their cell membrane receptors (ET(A)R and ET(B)R) are implicated in neoplastic pathogenesis. atrasentan, a potent, selective ET(A)R antagonist, has a direct effect on tumor proliferation, apoptosis, and angiogenesis. This study was ... Full text Link to item Cite

Phase II trial of B7-1 (CD-86) transduced, cultured autologous tumor cell vaccine plus subcutaneous interleukin-2 for treatment of stage IV renal cell carcinoma.

Journal article J Immunother · January 2008 We report a single center phase II trial of sequential vaccination followed with vaccine plus interleukin-2 (IL-2). Vaccination consisted of autologous cells cultured from primary tumor or resected metastasis, transduced to express B7.1 surface molecule an ... Full text Link to item Cite

Feasibility and efficacy of molecular analysis-directed individualized therapy in advanced non-small-cell lung cancer.

Journal article J Clin Oncol · July 1, 2007 PURPOSE: The treatment of patients with advanced non-small-cell lung cancer (NSCLC) is based on clinical trials experience. Molecular characteristics that impact metabolism and efficacy of chemotherapeutic agents are not used for decision making. Ribonucle ... Full text Link to item Cite

An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model.

Journal article Scand J Immunol · May 2007 CD40-mediated interactions play an important role in the response to a variety of diseases, including cancer. Engagement of CD40 on antigen-presenting cells, namely dendritic cells (DC), by CD40L leads to maturation and up-regulation of co-stimulatory mole ... Full text Link to item Cite

Phase I study of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors: preliminary evidence of activity in small cell and neuroendocrine carcinomas.

Journal article Cancer · April 1, 2007 BACKGROUND: The objective of this study was to determine the maximum tolerated dose and dose-limiting toxicity (DLT) of carboplatin in combination with gemcitabine and irinotecan in patients with solid tumors. METHODS: Patients with solid tumors who were n ... Full text Link to item Cite

Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody.

Journal article J Clin Oncol · March 1, 2007 PURPOSE: The cell-surface molecule CD40 activates antigen-presenting cells and enhances immune responses. CD40 is also expressed by solid tumors, but its engagement results in apoptosis. CP-870,893, a fully human and selective CD40 agonist monoclonal antib ... Full text Link to item Cite

A phase-I trial using a universal GM-CSF-producing and CD40L-expressing bystander cell line (GM.CD40L) in the formulation of autologous tumor cell-based vaccines for cancer patients with stage IV disease.

Journal article Ann Surg Oncol · February 2007 BACKGROUND: Significant antitumor T-cell responses are generated in vitro when human lymphocytes are stimulated with autologous tumor cells in the presence of bystander cells transfected with CD40L and GM-CSF. Our goal was to test this bystander-based vacc ... Full text Link to item Cite

All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients.

Journal article Cancer Res · September 15, 2006 Abnormal dendritic cell differentiation and accumulation of immature myeloid suppressor cells (ImC) is one of the major mechanisms of tumor escape. We tested the possibility of pharmacologic regulation of myeloid cell differentiation using all-trans-retino ... Full text Link to item Cite

Sequential oral 9-nitrocamptothecin and etoposide: a pharmacodynamic- and pharmacokinetic-based phase I trial.

Journal article Mol Cancer Ther · August 2006 PURPOSE: Resistance to topoisomerase (topo) I inhibitors has been related to down-regulation of nuclear target enzyme, whereas sensitization to topo II inhibitors may result from induction of topo II by topo I inhibitors. Here, we evaluated a sequence-spec ... Full text Link to item Cite

Surgical excision combined with autologous whole tumor cell vaccination is an effective therapy for murine neuroblastoma.

Journal article J Pediatr Surg · August 2006 BACKGROUND: Although a whole tumor cell vaccine strategy based on the synergistic action of granulocyte macrophage-colony-stimulating factor (GM-CSF) transduced tumor cells and CpG oligodeoxynucleotides induces potent tumor-specific immunity, such therapy ... Full text Link to item Cite

Combination of p53 cancer vaccine with chemotherapy in patients with extensive stage small cell lung cancer.

Journal article Clin Cancer Res · February 1, 2006 PURPOSE: The initial goal of this study was to test the immunologic and clinical effects of a new cancer vaccine consisting of dendritic cells (DC) transduced with the full-length wild-type p53 gene delivered via an adenoviral vector in patients with exten ... Full text Link to item Cite

A GM-CSF/CD40L producing cell augments anti-tumor T cell responses.

Journal article J Surg Res · May 15, 2005 BACKGROUND: Tumors evade T cell-mediated rejection despite the presence of tumor associated antigens (TAAs) and T cells specific for these TAAs in cancer patients. Therapeutic tumor vaccines are being developed to prevent this evasion. Previous reports rev ... Full text Link to item Cite

Phase II study of first-line sequential chemotherapy with gemcitabine-carboplatin followed by docetaxel in patients with advanced non-small cell lung cancer.

Journal article Oncology · 2005 RATIONALE: Despite the use of novel chemotherapeutic agents, patients with advanced non-small cell lung cancer (NSCLC) continue to show a poor survival. OBJECTIVES: To assess the safety and efficacy of a novel sequential and putatively non-cross-resistant ... Full text Link to item Cite

Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses.

Journal article Cancer Res · August 15, 2004 T cells infiltrating tumors have a decreased expression of signal transduction proteins, a diminished ability to proliferate, and a decreased production of cytokines. The mechanisms causing these changes have remained unclear. We demonstrated recently that ... Full text Link to item Cite

Erratum: Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes (Journal of Clinical Investigation (2004) 114 (280-290) DOI:10.1172/JCI200421583)

Journal article Journal of Clinical Investigation · August 1, 2004 Full text Cite

Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes.

Journal article J Clin Invest · July 2004 One mechanism contributing to immunologic unresponsiveness toward tumors may be presentation of tumor antigens by tolerogenic host APCs. We show that mouse tumor-draining LNs (TDLNs) contained a subset of plasmacytoid DCs (pDCs) that constitutively express ... Full text Link to item Cite

Current developments of immunotherapy in the clinic.

Journal article Curr Opin Immunol · April 2004 The clinical application of immunotherapy for cancer is rapidly moving forward in multiple areas, including the adoptive transfer of anti-tumor-reactive T cells and the use of 'therapeutic' vaccines. Recently, both clinical and immunological endpoints have ... Full text Link to item Cite

Specific antitumour vaccine for renal cancer.

Journal article Lancet · February 21, 2004 Full text Link to item Cite

Cell-based immune therapy for metastatic renal cancer.

Journal article Expert Rev Anticancer Ther · December 2003 An exciting group of investigational therapies for metastatic renal cancer use cellular preparations. Technical advances accommodate testing strategies to repair, bypass or direct the immune system to defeat the pathologic absence of effective antitumor re ... Full text Link to item Cite

Pattern of recruitment of immunoregulatory antigen-presenting cells in malignant melanoma.

Journal article Lab Invest · October 2003 The mechanism by which the immune system of a tumor-bearing host acquires tolerance toward tumor antigens is still elusive. Antigen-presenting cells (APCs) are critical regulators of the decision between immune response and tolerance. APCs that express the ... Full text Link to item Cite

Gene therapy for lung cancer.

Journal article Mol Biotechnol · October 2003 Lung cancer continues to be the largest killer of Americans due to cancer. Although progress has been made, with advances in chemotherapy, the majority of patients diagnosed with lung cancer ultimately succumb to the disease. A better understanding of the ... Full text Link to item Cite

Novel therapies for renal cell carcinoma--an update.

Journal article Expert Opin Investig Drugs · April 2003 This article reviews the recent progress in the search for new treatments for renal cell cancer (RCC), based on a variety of preclinical models or strategies. Some recent clinical trials addressing migrating treatments from other cancers onto RCC and novel ... Full text Link to item Cite

Gefitinib (ZD1839) in previously treated advanced non-small-cell lung cancer: experience from a single institution.

Journal article Cancer Control · 2003 BACKGROUND: We conducted an analysis of gefitinib in patients with advanced non-small-cell lung cancer (NSCLC) to assess the antitumor efficacy of this epidermal growth factor receptor tyrosine kinase inhibitor. METHODS: Our single-center, prospective land ... Full text Link to item Cite

Gene therapy for lung cancer. An introduction.

Journal article Methods Mol Med · 2003 Incremental progress will likely continue to be made in the treatment of lung cancer using the conventional treatment modalities. However, there is now hope that the development of noncross-resistant modalities that can be accomplished using the technology ... Full text Link to item Cite

Potential regulatory function of human dendritic cells expressing indoleamine 2,3-dioxygenase.

Journal article Science · September 13, 2002 Antigen-presenting cells (APCs) can induce tolerance or immunity. We describe a subset of human APCs that express indoleamine 2,3-dioxygenase (IDO) and inhibit T cell proliferation in vitro. IDO-positive APCs constituted a discrete subset identified by coe ... Full text Link to item Cite

Indoleamine 2,3-dioxygenase contributes to tumor cell evasion of T cell-mediated rejection.

Journal article Int J Cancer · September 10, 2002 The priming of an appropriate anti-tumor T cell response rarely results in the rejection of established tumors. The characteristics of tumors that allow them to evade a T cell-mediated rejection are unknown for many tumors. We report on evidence that the e ... Full text Link to item Cite

Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma.

Journal article J Urol · May 2002 PURPOSE: A reason that the immune system may fail to reject tumors is that T cells encounter tumor antigen derived peptides on the surface of tumor cells in a tolerizing rather than activating context since tumor cells do not express T cell co-stimulatory ... Link to item Cite

Advances in gene therapy for malignant melanoma.

Journal article Cancer Control · 2002 BACKGROUND: The recent developments in the field of gene transfer have advanced the use of gene therapy as a novel strategy against a variety of human malignancies. Due to its unique set of characteristics, melanoma represents a suitable target for the cli ... Full text Link to item Cite

Novel therapies for renal cell carcinoma.

Journal article Expert Opin Investig Drugs · June 2001 Metastatic renal cell cancer remains a disease which is difficult to treat medically. Prognosis often depends more on intrinsic disease features than on treatment choices. In this review, we examine novel therapies and scientific directions surrounding the ... Full text Link to item Cite

B7-1 gene-modified autologous tumor-cell vaccines for renal-cell carcinoma.

Journal article World J Urol · April 2000 In recent years, interest in the development of immunologic approaches to malignancies has increased, and there is good evidence that the growth of renal-cell carcinoma (RCC) can be modulated by the host's immune system. Indeed, use of the immunomodulatory ... Full text Link to item Cite

Gene therapy for lung cancer.

Journal article Curr Opin Oncol · March 2000 The advances that have been made over the past decade in the field of gene transfer as well as in the fields of immunology and the molecular biology of tumorigenesis have brought to reality the possibility of using gene transfer as an anti-cancer treatment ... Full text Link to item Cite

Human cut-like repressor protein binds TGFbeta type II receptor gene promoter.

Journal article Arch Biochem Biophys · November 15, 1999 Resistance to the growth inhibitory effects of transforming growth factor beta (TGFbeta) has been associated with decreased levels of the TGFbeta type II receptor (TbetaR-II) and has been correlated with tumorigenicity. Previously, we reported an A --> G m ... Full text Link to item Cite

Identification of an enhancer element in the mouse B7-1 promoter.

Journal article Immunogenetics · October 1999 Full text Link to item Cite

B7-1 gene-modified tumor cell vaccines.

Journal article Curr Opin Mol Ther · February 1999 Link to item Cite

Immunologic nonresponsiveness to tumors.

Journal article Crit Rev Oncog · 1998 Over the past several years it has become clear that malignant cells express a variety of tumor associated antigens, and T cells reactive to these antigens have been identified. However, the T cells are not effective in rejecting tumors. In general, T cell ... Full text Link to item Cite

Improving Our Management of Non-Small Cell Lung Cancer and Mesothelioma.

Journal article Cancer Control · July 1997 Full text Link to item Cite

Ten best readings on lung cancer and mesothelioma

Journal article Cancer Control · January 1, 1997 Full text Cite

A mutation in the transforming growth factor beta type II receptor gene promoter associated with loss of gene expression.

Journal article Cancer Res · November 1, 1996 Expression of transforming growth factor beta type II receptors (TbetaR-IIs) is either greatly decreased or absent in many tumors, implying that the loss of TbetaR-II function is one of the mechanisms leading to tumor development. In this report, we examin ... Link to item Cite

Renal ischemic-reperfusion injury in L-selectin-deficient mice.

Journal article Am J Physiol · August 1996 L-selectin on leukocyte surfaces mediates cell rolling on endothelium. L-selectin blockade with antibodies attenuated ischemic-reperfusion injury (IRI) in heart and skeletal muscle, but its role in renal IRI is unknown. We evaluated the role of L-selectin ... Full text Link to item Cite

Cloning and partial characterization of the mouse B7-1 promoter.

Journal article Immunogenetics · 1996 Full text Link to item Cite

Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells.

Journal article Cancer Res · September 15, 1995 In this study, we report the occurrence of missense mutations of the transforming growth factor beta (TGF beta) type II receptor gene in two human squamous head and neck carcinoma cell lines. Both mutations are G:C-->C:G transversions, which result in the ... Link to item Cite

B7-1 expression by a non-antigen presenting cell-derived tumor.

Journal article Cancer Res · June 1, 1995 The existence of a naturally occurring immunosurveillance against neoplastic cells is controversial. A difficulty with this concept is that tumor-specific antigen-reactive T cells would not be expected to become activated after encountering tumor cells, si ... Link to item Cite

Mechanisms of immune tolerance induction through the thymic expression of a peripheral tissue-specific protein.

Journal article Int Immunol · May 1995 A major process through which the immune system becomes tolerant to self proteins involves the deletion of self reactive cells in the thymus. However, T cells reactive to peripheral tissue-specific proteins can escape this deletion and become tolerized in ... Full text Link to item Cite

Attachment of tumor cells to endothelial monolayers: detection of surface molecules involved in cell-cell binding.

Journal article Clin Immunol Immunopathol · November 1989 Trypsinization of P815 mastocytoma cells interferes with their ability to bind to endothelial monolayers in vitro, suggesting the involvement of proteins in cell-cell binding. Binding is also dependent upon divalent cations. Incubation of tumor cells with ... Full text Link to item Cite

The elaboration of a small molecular weight cytostatic factor by lymphoblastoid lines and activated lymphocytes.

Journal article Lymphokine Res · 1986 In this study, it was observed that the B lymphoid cell line RPMI 8392 produced a tumor cell cytostatic factor that is of lower molecular weight than previously described cytostatic proteins but of greater molecular weight than arachidonate metabolites. Th ... Link to item Cite

Adherence of tumor cells to endothelial monolayers: inhibition by lymphokines.

Journal article Cell Immunol · October 15, 1985 Tumor cells can adhere to endothelial cell monolayers in vitro. The kinetics of this reaction are rapid; 50% of maximal binding occurs by 30 min of incubation. In the case of the P815 mastocytoma, the maximal percentage of binding is approximately 70%, sug ... Full text Link to item Cite

Inhibition of tumor cell proliferation by a factor released by a B-lymphoid cell line

Journal article Federation Proceedings · January 1, 1985 Cite